Receiving the FDA’s clearance to proceed with our Phase 2 clinical trial for TPST-1495, our second clinical program, in FAP marks an important step forward in developing new treatment options for ...
A century ago, measles was killing a thousand people in the U.S. every year. By 2000, vaccines had all but eliminated the ...
CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...
Tempest Therapeutics (TPST) announced that the Cancer Prevention Clinical Trials Network received a “Study May Proceed” letter from the U.S.
Tempest Therapeutics, Inc. has announced that the U.S. FDA has granted a "Study May Proceed" letter for their Phase 2 clinical trial of TPST-1495, a novel dual receptor inhibitor aimed at treating ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Sigma Planning Corp cut its stake in shares of Snowflake Inc. (NYSE:SNOW – Free Report) by 42.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,992 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results